The appearance of facial foundation cosmetics applied after metronidazole gel 1%

Cutis

Volumn 87, Issue 5, 2011, Pages 251-259

  Draelos, Zoe D ^a   Colón, Luz E ^b   Preston, Norman ^b   Johnson, Lori A ^b   Gottschalk, Ronald W ^b  

^a DERMATOLOGY CONSULTING SERVICES   (United States)

^b Galderma Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COSMETIC; DERMATOLOGICAL AGENT; METRONIDAZOLE;

ADULT; AGED; ARTICLE; CHEMISTRY; CLINICAL TRIAL; ERYTHEMA; FEMALE; GEL; HOSPITALIZATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; ROSACEA;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; COSMETICS; DERMATOLOGIC AGENTS; ERYTHEMA; FEMALE; GELS; HUMANS; METRONIDAZOLE; MIDDLE AGED; ROSACEA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79960114807     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Barco D, Alomar A. Rosacea [in Spanish]. Actas Dermosifiliogr. 2008;99:244-256.
2. Crawford GH, Pelle MT, James WD. Rosacea: I. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341.
3. Ceilley RI. Advances in the topical treatment of acne and rosacea. J Drugs Dermatol. 2004;3(suppl 5):S12-S22.
4. Aksoy B, Altaykan-Hapa A, Egemen D, et al. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163:719-725.
5. Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-912.
6. Abram K, Silm H, Maaroos HI, et al. Risk factors associated with rosacea [published online ahead of print October 23, 2009]. J Eur Acad Dermatol Venereol. 2010;24:565-571.
7. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. 2005;19:273-285.
8. Odom R, Dahl M, Dover J, et al; National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. Standard management options for rosacea, part 1: overview and broad spectrum of care. Cutis. 2009;84:43-47.
9. What is rosacea? National Rosacea Society Web site. http://www.rosacea.org/index.php. Accessed April 20, 2011.
10. Wilkin JK. Rosacea. pathophysiology and treatment. Arch Dermatol. 1994;130:359-362.
11. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician. 2002;66:435-440.
12. New studies show high incidence of rosacea and possible new causes. Rosacea Review. Summer 2007. http://www.rosacea.org/rr/2007/summer/article_1.php. Accessed March 9, 2011.
13. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
14. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78:97-100.
15. Butterwick KJ, Butterwick LS, Han A. Laser and light therapies for acne rosacea. J Drugs Dermatol. 2006;5:35-39.
16. Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79:73-80.
17. Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007;12:1-5, 9.
18. Liu RH, Smith MK, Basta SA, et al. Azelaic acid in the treatment of papulopustular rosacea: a systematic review of randomized controlled trials. Arch Dermatol. 2006;142:1047-1052.
19. Gupta MA, Gupta AK, Chen SJ, et al. Comorbidity of rosacea and depression: an analysis of the national ambulatory medical care survey and national hospital ambulatory care survey-outpatient department data collected by the U.S. national center for health statistics from 1995 to 2002. Br J Dermatol. 2005;153:1176-1181.
20. Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 2: options according to subtype. Cutis. 2009;84:97-104.
21. Korting HC, Schöllmann C. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol. 2009;23:876-882.
22. Nielsen PG. Treatment of rosacea with 1% metronidazole cream. a double-blind study. Br J Dermatol. 1983;108:327-332.
23. Conde JF, Yelverton CB, Balkrishnan R, et al. Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol. 2007;6:495-498.
24. Del Rosso JQ. Acne and rosacea [letter]. J Drugs Dermatol. 2008;7:525.
25. Jappe U, Schnuch A, Uter W. Rosacea and contact allergy to cosmetics and topical medicaments-retrospective analysis of multicentre surveillance data 1995-2002. Contact Dermatitis. 2005;52:96-101.
26. Draelos ZD, Johnson LA, Colon LE, et al. An evaluation of the acceptance of metronidazole gel 1% when used with facial cosmetics in rosacea patients. J Am Acad Dermatol. 2009;60(suppl 1):AB20.
27. Del Rosso JQ, Bikowski J. Topical metronidazole combination therapy in the clinical management of rosacea. J Drugs Dermatol. 2005;4:473-480.
28. About MetroGel 1%. MetroGel Web site. http://www.metrogel.com/Consumer/AboutMetroGel/WhyMetroGel.aspx. Accessed July 22, 2010.
29. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450.
30. Ziel K, Yelverton CB, Balkrishnan R, et al. Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. J Drugs Dermatol. 2005;4:727-731.
31. Colón LE, Johnson LA, Gottschalk RW. Cumulative irritation potential among metronidazole gel 1%, metronidazole gel 0.75%, and azelaic acid gel 15%. Cutis. 2007;79:317-321.
32. Jorizzo JL, Lebwohl M, Tobey RE. The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial. J Am Acad Dermatol. 1998;39:502-504.
33. van Zuuren EJ, Gupta AK, Gover MD, et al. Systematic review of rosacea treatments [published online ahead of print November 7, 2006]. J Am Acad Dermatol. 2007;56:107-115.
34. Beutner K, Calvarese B, Graeber M. A multi-center, investigator-blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea. J Am Acad Dermatol. 2005;52(suppl 1):P101.
35. Draelos ZD. Assessment of skin barrier function in rosacea patients with a novel 1% metronidazole gel. J Drugs Dermatol. 2005;4:557-562.
36. Colon LE, Rizer R, Johnson LA, et al. Corneometric assessment of skin hydration following the application of metronidazole 1% gel. J Am Acad Dermatol. 2007;56(suppl 2):AB13.
37. Dow G, Basu S. A novel aqueous metronidazole 1% gel with hydrosolubilizing agents (HSA-3). Cutis. 2006;77(suppl 4):18-26.
38. Jappe U, Schäfer T, Schnuch A, et al. Contact allergy in patients with rosacea: a clinic-based, prospective epidemiological study [published online ahead of print April 29, 2008]. J Eur Acad Dermatol Venereol. 2008;22:1208-1214.
39. Wolf R, Orion E, Matz H. Co-existing sensitivity to metronidazole and isothiazolinone. Clin Exp Dermatol. 2003;28:506-507.
40. MetroGel [package insert]. Fort Worth, TX: Galderma Laboratories, LP; 2007.